- Shares of Novavax (NVAX +7.5%) are outperforming on the session.
- Helping the cause is Wedbush's Gregory Wade, who is out raising his price target on the name to $12 (from $4), representing upside of 210% from Friday's close.
- The call comes as Wade "reformats and revises" his financial projections to include "potential sales of an RSV-F combination product."
- More color: "We now project NVAX will launch a combination RSV-F vaccine in H2 2018 and H2 2019 in the US and Europe, respectively, and that sales will reach nearly $1B by 2020."
From other sites
at CNBC.com (Jan 15, 2015)
at CNBC.com (Jun 6, 2014)
at CNBC.com (Apr 23, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs